Functionalized nanozyme with drug loading for enhanced tumour combination treatment of catalytic therapy and chemotherapy.
J Mater Chem B
; 11(29): 6889-6895, 2023 07 26.
Article
in En
| MEDLINE
| ID: mdl-37377123
ABSTRACT
Nanozyme-based tumour catalytic therapy has attracted widespread attention in recent years, but the therapeutic efficacy is limited due to the trapping of hydroxyl radicals (ËOH) by endogenous glutathione (GSH) in the tumour microenvironment (TME). Zr/Ce-MOFs/DOX/MnO2 is constructed in this work to serve as a new kind of nanozyme for combination chemotherapy and catalytic treatment. Zr/Ce-MOFs can produce ËOH in a mimic TME, and the MnO2 on the surface could deplete the GSH, further promoting the ËOH generation. The pH/GSH dual stimulation accelerates the release of anticancer drug doxorubicin (DOX) in tumour tissue for enhanced tumour chemotherapy. Moreover, Mn2+ produced by the reaction of Zr/Ce-MOFs/DOX/MnO2 and GSH can be used as the contrast agent for T1-MRI. The potential antitumour effect of Zr/Ce-MOFs/DOX/MnO2 is demonstrated by in vitro and in vivo cancer treatment tests. This work thus provides a new nanozyme-based platform for enhanced combination chemotherapy and catalytic treatment for tumours.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoplasms
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
J Mater Chem B
Year:
2023
Document type:
Article
Affiliation country:
China